EC approves Bristol Myers’ anti-BCMA CAR T-cell treatment for multiple myeloma
Abecma has been approved to treat adult relapsed and refractory multiple myeloma patients who have received a minimum of three prior therapies and have experienced disease progression on
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.